India's Biocon sees oral insulin partner by March
(For other news from the Reuters India Investment Summit, click here)
BANGALORE Nov 23 (Reuters) - Biocon Ltd, India's largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top executive said on Wednesday .
"We are in advanced discussions with potential partners," Biocon's Managing Director Kiran Mazumdar-Shaw told the Reuters India Investment Summit in Bangalore.
In January, Biocon had said it was looking for a partner after its oral insulin, IN-105, failed to meet the main goal of an Indian late-stage trial in patients with type-2 diabetes.
Mazumdar-Shaw, however, declined to name any potential partners.
She also said the planned IPO of its contract research organisation, Syngene, was on track.
(For summit blog: blogs.reuters.com/summits/)
(For more on the Reuters India Investment Summit, see ) (Reporting by Anand Basu, Jochelle Mendonca and Aftab Ahmed in Bangalore. Editing by Sriraj Kalluvila, Saumyadeb Chakrabarty)
- Tweet this
- Share this
- Digg this
- India's demands block $1 trillion WTO deal on customs rules
- India, U.S. stress strategic ties but tensions remain
- Panasonic confirms will invest in $5 billion Tesla battery plant
- Millions of jellyfish-like creatures wash up on western U.S. beaches
- Israel, Palestinians locked in vicious circle of Gaza wars
The World Trade Organization failed on Thursday to reach a deal to standardise customs rules, which would have been the first global trade reform in two decades but was blocked by India's demands for concessions on agricultural stockpiling. Full Article
India group ICVL to nearly triple coal output from mine bought from Rio Tinto. Full Article